The primary objective is to assess whether inhaling vaporized cannabis ameliorates chronic pain in patients with sickle cell disease (SCD). As these patients will all be on chronic opioid analgesics, the investigators will also assess the possible synergistic affect between inhaled cannabis and opioids. The investigators will also assess the clinical safety of the concomitant use of cannabinoids and these opioids in patients with SCD by monitoring the short-term side effects associated with combined therapy. Finally, the investigators will evaluate the short-term effects of inhaled cannabis on markers of inflammation and disease progression in patients with SCD.


More information: clinicaltrials.gov, ITHANET Clinical Trials

thalamoss logo 400

The Kick-Off/Scientific meeting of THALAMOSS will be held on January 14-15 at Ferrara, Italy. THALAMOSS, which stands for THALAssaemia MOdular Stratification System, is a research project funded from the 7th Framework Programme of Research & Development of the European Union. The project brings together 13 leading European and US Research Institutions, as well as European and Israeli SMEs.  The ITHANET Portal is one of the partners of the THALAMOSS project.

The Scientific Meeting will be held on January 14 and is is entitled "From basic research to novel applications on the road of personalized treatment of thalassaemia". According to the meeting announcement: "The specific aims of the THALAMOSS Project will be achieved by the development of novel methods for associating variation in genomic data with phenotypic variation. THALAMOSS will combine cutting edge computing technology with optimized algorithms to mine the unique datasets provided through the proposed project for biologically and medically relevant patterns that can be reliably associated with specific patient groups, treatment response and disease progression. In addition to stratification of patient samples for their molecular properties, the proposed project will also analyse responsiveness to advanced therapeutic approaches to classify patient samples, analysing this responsiveness both as a consequence of molecular properties and as a determinant of the success of novel therapies.

More information about the scientific meeting can be found here.

MGH Logo

The main purpose of this pilot study is to examine the outcome of a combined bone marrow and kidney transplant from a partially matched related (haploidentical or "haplo") donor. The aim of the combined transplant is to treat both underlying blood disorders and kidney diseases. Ten people are expected to participate in this study.


More information: clinicaltrials.gov, ITHANET Clinical Trials

Duke logo

In this study, Laser Doppler Flowmetry (LDF), Laser Doppler Imaging (LDI), Orthogonal Polarization Spectral Imaging (OPSI), and Optical Coherence Tomography (OCT)will be used to assess differences in microvascular function and density of oral mucosa and skin in subjects with 1) autoimmune diseases with cutaneous involvement: systemic sclerosis (SSc), morphea, dermatomyositis, cutaneous lupus and vasculitis, 2) sickle cell disease (SCD) and 3) chronic graft-versus-host disease (GVHD) compared to healthy subjects. The microvascular changes will be compared to overall treatment response in patients with scleroderma and chronic GVHD as assessments will be made before and after the patients start treatment for their diseases and determine if these imaging techniques provide valuable and reproducible data when assessing a patient's response to treatment for those diseases. In addition, the application of Acoustic Radiation Force Impulse (ARFI) in determining cutaneous thickness in patients with SSc, GVHD and morphea will be evaluated.


More Information: clinicaltrials.gov, ITHANET Clinical Trials


The study will evaluate the safety and tolerability of ACE-536 in beta-thalassemia intermedia patients with anemia and the ability of ACE-536 to generate an erythroid response in these patients. Eligible patients may have received up to 6 red blood cell transfusions during the previous 12 months (with none during the 8-week period prior to study enrollment). An erythroid response in this study is defined as an increase in hemoglobin of at least 1.5 g/dL from pretreatment baseline values, sustained for at least 14 days, in the absence of a red blood cell transfusion. The expected starts in December 2012 and the expected completion date is November 2014.


More information: clinicaltrials.gov, ITHANET Clinical Trials